KRAS G12D in mucinous/low-grade serous ovarian — no approved drug; trial-only (MRTX1133).
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-KRAS-G12D-OVARIAN |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-OVARIAN |
| Sources | SRC-CIVIC SRC-NCCN-OVARIAN-2025 |
Actionability Facts
| Biomarker | BIO-RAS-MUTATION |
|---|---|
| Variant | KRAS G12D |
| Disease | DIS-OVARIAN |
| ESCAT tier | IIIB |
| Evidence summary | KRAS G12D in mucinous/low-grade serous ovarian — no approved drug; trial-only (MRTX1133). |
Notes
ESCAT IIIB. FLAG: dedicated BIO-KRAS-G12D would improve granularity.
Used By
No reverse references found in the YAML corpus.